Ung Thư Dạ Dày: Dịch Tễ Học, Yếu Tố Nguy Cơ, Phân Loại, Đặc Điểm Genom và Chiến Lược Điều Trị

Yusefi, 2018, Risk Factors for Gastric Cancer: A Systematic Review, Asian Pac. J. Cancer Prev., 19, 591

Zhang, 2016, Gastric cancer: Somatic genetics as a guide to therapy, J. Med. Genet., 54, 305, 10.1136/jmedgenet-2016-104171

Gao, 2018, Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell, World J. Gastroenterol., 24, 2567, 10.3748/wjg.v24.i24.2567

Park, 2014, Prevention Strategies for Gastric Cancer: A Global Perspective, Clin. Endosc., 47, 478, 10.5946/ce.2014.47.6.478

Kong, 2012, Comparison of the clinicopathological characteristics of young and Elderly patients with gastric carcinoma: A meta analysis, J. Surg. Oncol., 106, 346, 10.1002/jso.23004

Kunisaki, 2006, Clinicopathological Features of Gastric Carcinoma in Younger and Middle-Aged Patients: A Comparative Study, J. Gastrointest. Surg., 10, 1023, 10.1016/j.gassur.2006.03.001

Llanos, 2005, Survival of Young Patients after Gastrectomy for Gastric Cancer, World J. Surg., 30, 17, 10.1007/s00268-005-7935-5

Takatsu, 2015, Clinicopathological features of gastric cancer in young patients, Gastric Cancer, 19, 472, 10.1007/s10120-015-0484-1

Milne, 2007, Early onset gastric cancer: On the road to unraveling gastric carcinogenesis, Curr. Mol. Med., 7, 15, 10.2174/156652407779940503

Lauren, 1965, The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification, Acta Pathol. Microbiol. Scand., 64, 31, 10.1111/apm.1965.64.1.31

Bosman, F.T., Carneiro, F., Hruban, R.H., and Theise, N.D. (2010). WHO Classification of Tumours of the Digestive System, IARC. [4th ed.].

Vogelaar, 2017, Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing, Eur. J. Hum. Genet., 25, 1246, 10.1038/ejhg.2017.138

Pernot, 2015, Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge, World J. Gastroenterol., 21, 11428, 10.3748/wjg.v21.i40.11428

Milne, 2010, Early-onset gastric cancer: Learning lessons from the young, World J. Gastrointest. Oncol., 2, 59, 10.4251/wjgo.v2.i2.59

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int. J. Cancer, 127, 2893, 10.1002/ijc.25516

Jemal, 2010, Global Patterns of Cancer Incidence and Mortality Rates and Trends, Cancer Epidemiol. Biomark. Prev., 19, 1893, 10.1158/1055-9965.EPI-10-0437

Ang, 2014, Clinical epidemiology of gastric cancer, Singap. Med. J., 55, 621, 10.11622/smedj.2014174

Matsuda, 2013, The 5-Year Relative Survival Rate of Stomach Cancer in the USA, Europe and Japan, Jpn. J. Clin. Oncol., 43, 1157, 10.1093/jjco/hyt166

Ferro, 2014, Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype, Eur. J. Cancer, 50, 1330, 10.1016/j.ejca.2014.01.029

Edwards, 2013, Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer, 120, 1290, 10.1002/cncr.28509

Kaneko, 2001, Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989, Br. J. Cancer, 84, 400, 10.1054/bjoc.2000.1602

Sitarz, 2018, Gastric cancer: Epidemiology, prevention, classification, and treatment, Cancer Manag. Res., 10, 239, 10.2147/CMAR.S149619

Yaghoobi, 2009, Family history and the risk of gastric cancer, Br. J. Cancer, 102, 237, 10.1038/sj.bjc.6605380

Lauwers, 2014, Familial Gastric Cancers, Pathol. Case Rev., 19, 66, 10.1097/PCR.0000000000000030

Boland, 2017, Historical Perspective on Familial Gastric Cancer, Cell. Mol. Gastroenterol. Hepatol., 3, 192, 10.1016/j.jcmgh.2016.12.003

Pinheiro, 2014, Hereditary diffuse gastric cancer–Pathophysiology and clinical management, Best Pr. Res. Clin. Gastroenterol., 28, 1055, 10.1016/j.bpg.2014.09.007

Lim, S.H., Kwon, J.-W., Kim, N., Kim, G.H., Kang, J.M., Park, M.J., Yim, J.Y., Kim, H.U., Baik, G.H., and Seo, G.S. (2013). Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years. BMC Gastroenterol., 13.

Corso, G., and Roviello, F. (2013). Frequency of Familial Gastric Cancer. Spotlight on Familial and Hereditary Gastric Cancer, Springer.

Kim, 2014, Gene-diet interactions in gastric cancer risk: A systematic review, World J. Gastroenterol., 20, 9600, 10.3748/wjg.v20.i28.9600

Zhang, 2011, Salt taste preference, sodium intake and gastric cancer in China, Asian Pac. J. Cancer Prev., 12, 1207

Keszei, 2012, Dietary N-nitroso compounds, endogenous nitrosation, and the risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study, Am. J. Clin. Nutr., 97, 135, 10.3945/ajcn.112.043885

Moy, 2010, Alcohol and tobacco use in relation to gastric cancer: A prospective study of men in Shanghai, China, Cancer Epidemiol. Biomark. Prev., 19, 2287, 10.1158/1055-9965.EPI-10-0362

Duell, 2011, Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, Am. J. Clin. Nutr., 94, 1266, 10.3945/ajcn.111.012351

Shin, 2011, Association between alcohol intake and risk for gastric cancer with regard to ALDH2 genotype in the Korean population, Int. J. Epidemiol., 40, 1047, 10.1093/ije/dyr067

Ishaq, 2015, Helicobacter pylori and gastric cancer: A state of the art review, Gastroenterol. Hepatol. Bed Bench, 8, S6

Khatoon, 2016, Role of Helicobacter pylori in gastric cancer: Updates, World J. Gastrointest. Oncol., 8, 147, 10.4251/wjgo.v8.i2.147

Chang, 2018, The impacts of H. pylori virulence factors on the development of gastroduodenaldiseases, J. Biomed. Sci., 25, 1, 10.1186/s12929-018-0466-9

Roesler, 2014, Virulence Factors ofHelicobacter pylori:A Review, Clin. Med. Insights Gastroenterol., 7, 9, 10.4137/CGast.S13760

Baj, J., Brzozowska, K., Forma, A., Maani, A., Sitarz, E., and Portincasa, P. (2020). Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis. Int. J. Mol. Sci., 21.

Baj, J., Korona-Glowniak, I., Forma, A., Maani, A., Sitarz, E., Rahnama-Hezavah, M., Radzikowska, E., and Portincasa, P. (2020). Mechanisms of the Epithelial–Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer. Cells, 9.

Iizasa, 2012, Epstein-Barr Virus (EBV)-associated Gastric Carcinoma, Viruses, 4, 3420, 10.3390/v4123420

Fukayama, 1994, Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infectionof the stomach, Lab Investig., 71, 73

Camargo, 2011, Determinants of Epstein-Barr virus-positive gastric cancer: An international pooled analysis, Br. J. Cancer, 105, 38, 10.1038/bjc.2011.215

Hu, 2012, Gastric cancer: Classification, histology and application of molecular pathology, J. Gastrointest. Oncol., 3, 251

2011, WHO Classification of digestive tumors: The fourth edition, Ann. Pathol., 31, S27

Sarbia, 2004, Pathology of upper gastrointestinal malignancies, Semin. Oncol., 31, 465, 10.1053/j.seminoncol.2004.04.020

Werner, 2001, Gastric adenocarcinoma: Pathomorphology and molecular pathology, J. Cancer Res. Clin. Oncol., 127, 207, 10.1007/s004320000195

Kikuchi, 1996, Association between Family History and Gastric Carcinoma among Young Adults, Jpn. J. Cancer Res., 87, 332, 10.1111/j.1349-7006.1996.tb00226.x

Forman, 2006, Gastric cancer: Global pattern of the disease and an overview of environmental risk factors, Best Pract. Res. Clin. Gastroenterol., 20, 633, 10.1016/j.bpg.2006.04.008

Correa, 1992, Human gastric carcinogenesis: A multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention, Cancer Res., 52, 6735

Skierucha, 2016, Molecular alterations in gastric cancer with special reference to the early-onset subtype, World J. Gastroenterol., 22, 2460, 10.3748/wjg.v22.i8.2460

Carvalho, 2004, Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age, J. Pathol., 204, 75, 10.1002/path.1602

Kokkola, 2002, Gastric carcinoma in young adults, Hepatogastroenterology, 48, 1552

Milne, 2006, Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers, Mod. Pathol., 19, 564, 10.1038/modpathol.3800563

Toftgaard, 1989, Gastric Cancer after Peptic Ulcer Surgery, Ann. Surg., 210, 159, 10.1097/00000658-198908000-00004

Sinning, 2007, Gastric stump carcinoma—Epidemiology and current concepts in pathogenesisand treatment, Eur. J. Surg. Oncol., 33, 133, 10.1016/j.ejso.2006.09.006

Viste, 1986, Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients, Lancet, 2, 502, 10.1016/S0140-6736(86)90368-5

Luo, 2018, CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis and Treatment, Front. Pharmacol., 9, 1421, 10.3389/fphar.2018.01421

Negri, 1992, Family history and the risk of stomach and colorectal cancer, Cancer, 70, 50, 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I

Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (1993–2019). Hereditary Diffuse Gastric Cancer. GeneReviews [Internet], University of Washington.

Guilford, 2007, A short guide to hereditary diffuse gastric cancer, Hered. Cancer Clin. Pr., 5, 183, 10.1186/1897-4287-5-4-183

Hansford, 2015, Hereditary Diffuse Gastric Cancer Syndrome, JAMA Oncol., 1, 23, 10.1001/jamaoncol.2014.168

Machlowska, J., Maciejewski, R., and Sitarz, R. (2018). The Pattern of Signatures in Gastric Cancer Prognosis. Int. J. Mol. Sci., 19.

Jimeno, 2008, HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target, Ann. Oncol., 19, 1523, 10.1093/annonc/mdn169

Wang, 2017, Clinicopathological factors associated with HER2-positive gastric cancer, Medicine, 96, e8437, 10.1097/MD.0000000000008437

Busuttil, 2014, Role of p53 in the progression of gastric cancer, Oncotarget, 5, 12016, 10.18632/oncotarget.2434

Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat. Med., 21, 449, 10.1038/nm.3850

Xing, 2017, Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients, OncoImmunology, 7, e1356144, 10.1080/2162402X.2017.1356144

Pilozzi, 2003, P73 gene mutations in gastric adenocarcinomas, Mol. Pathol., 56, 60, 10.1136/mp.56.1.60

Wang, 2011, Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma, Oncol. Lett., 2, 707, 10.3892/ol.2011.292

Wu, 2014, Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression, World J. Surg. Oncol., 12, 40, 10.1186/1477-7819-12-40

Gao, 2004, Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance, World J. Gastroenterol., 10, 2936, 10.3748/wjg.v10.i20.2936

Arici, 2009, Expression of retinoblastoma and cyclin D1 in gastric carcinoma, Neoplasma, 56, 63, 10.4149/neo_2009_01_63

Hayashi, 1997, High frequency of simultaneous loss of p16 and p16β gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach, Oncogene, 15, 1481, 10.1038/sj.onc.1201295

Feakins, 2000, p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma, Cancer, 89, 1684, 10.1002/1097-0142(20001015)89:8<1684::AID-CNCR6>3.0.CO;2-6

Boltin, 2013, Mucins in Gastric Cancer—An Update, J. Gastrointest. Dig. Syst., 3, 15519, 10.4172/2161-069X.1000123

Lee, 2001, MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: Their roles as prognostic indicators, Cancer, 92, 1427, 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L

Sandusky, 2002, Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays, Histopathology, 41, 65, 10.1046/j.1365-2559.2002.01403.x

Qiao, 2013, Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese, Med. Oncol., 30, 643, 10.1007/s12032-013-0643-3

Zhu, 2013, Knockdown of MDR1 Increases the Sensitivity to Adriamycin in Drug Resistant Gastric Cancer Cells, Asian Pac. J. Cancer Prev., 14, 6757, 10.7314/APJCP.2013.14.11.6757

Hayes, 1991, Glutathione S-transferase in humans in health and disease, Gut, 32, 813, 10.1136/gut.32.7.813

Yu, 2014, Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer, World J. Surg. Oncol., 12, 307, 10.1186/1477-7819-12-307

Bass, 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480

Polom, 2018, The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients, Surg. Innov., 25, 99, 10.1177/1553350617751461

Ballehaninna, 2012, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal, J. Gastrointest. Oncol., 3, 105

Feng, F., Tian, Y., Xu, G., Liu, Z., Liu, S., Zheng, G., Guo, M., Lian, X., Fan, D., and Zhang, H. (2017). Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer. BMC Cancer, 17.

Kochi, 2000, Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer, Gastric Cancer, 3, 177, 10.1007/PL00011715

Sisik, 2013, CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients, Asian Pac. J. Cancer Prev., 14, 4289, 10.7314/APJCP.2013.14.7.4289

Zhou, 2015, Preoperative Serum CEA and CA19-9 in Gastric Cancer—A Single Tertiary Hospital Study of 1,075 Cases, Asian Pac. J. Cancer Prev., 16, 2685, 10.7314/APJCP.2015.16.7.2685

Chen, 2017, Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer, Ann. Clin. Lab. Sci., 47, 260

Sawayama, 2018, The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer, Surg. Today, 48, 994, 10.1007/s00595-018-1684-1

Hasbahceci, 2018, Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: Are they prognostic factors?, Ann. R. Coll. Surg. Engl., 100, 257, 10.1308/rcsann.2018.0011

Sun, 2014, Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy, World J. Surg. Oncol., 12, 397, 10.1186/1477-7819-12-397

Song, 2015, Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis, Dis. Markers, 2015, 1

Yu, 2016, An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4, J. Gastrointest. Cancer, 49, 57, 10.1007/s12029-016-9912-7

Shen, 2018, Five common tumor biomarkers and CEA for diagnosing early gastric cancer, Medicine, 97, e0577, 10.1097/MD.0000000000010577

Elingarami, 2014, Applications of nanotechnology in gastric cancer: Detection and prevention by nutrition, J. Nanosci. Nanotechnol., 14, 932, 10.1166/jnn.2014.9008

Pera, 2006, Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC–EURGAST), Int. J. Cancer, 118, 2559, 10.1002/ijc.21678

International Agency for Research on Cancer (2003). Fruit and vegetables. IARC Handbooks of Cancer Prevention, IARC.

Graham, 2005, The time to eradicate gastric cancer is now, Gut, 54, 735, 10.1136/gut.2004.056549

Ford, 2014, Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials, BMJ, 348, g3174, 10.1136/bmj.g3174

Ma, 2012, Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality, J. Natl. Cancer Inst., 104, 488, 10.1093/jnci/djs003

Choi, 2014, Eradication of Helicobacter pylori After Endoscopic Resection of Gastric Tumors Does Not Reduce Incidence of Metachronous Gastric Carcinoma, Clin. Gastroenterol. Hepatol., 12, 793, 10.1016/j.cgh.2013.09.057

Fukase, 2008, Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial, Lancet, 372, 392, 10.1016/S0140-6736(08)61159-9

Tsubono, 2000, Screening for gastric cancer in Japan, Gastric Cancer, 3, 9, 10.1007/PL00011692

Choi, 2014, Screening for Gastric Cancer: The Usefulness of Endoscopy, Clin. Endosc., 47, 490, 10.5946/ce.2014.47.6.490

Karimi, 2014, Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention, Cancer Epidemiol. Biomark. Prev., 23, 700, 10.1158/1055-9965.EPI-13-1057

Matsumoto, 2013, Reduction of gastric cancer mortality by endoscopic and radiographic screening in an isolated island: A retrospective cohort study, Aust. J. Rural. Heal., 21, 319, 10.1111/ajr.12064

Hamashima, C., Ogoshi, K., Okamoto, M., Shabana, M., Kishimoto, T., and Fukao, A. (2013). A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS ONE, 8.

Swan, 2006, Current role of surgical therapy in gastric cancer, World J. Gastroenterol., 12, 372, 10.3748/wjg.v12.i3.372

Parisi, 2017, Minimally invasive surgery for gastric cancer: A comparison between robotic, laparoscopic and open surgery, World J. Gastroenterol., 23, 2376, 10.3748/wjg.v23.i13.2376

Facciorusso, 2014, Endoscopic submucosal dissection vs endoscopic mucosal resection for earlygastric cancer: A meta-analysis, World J. Gastrointest. Endosc., 6, 555, 10.4253/wjge.v6.i11.555

Son, 2016, Laparoscopic gastric cancer surgery: Current evidence and future perspectives, World J. Gastroenterol., 22, 727, 10.3748/wjg.v22.i2.727

Gholami, 2017, Minimally Invasive Surgical Approaches to Gastric Resection, Surg. Clin. North Am., 97, 249, 10.1016/j.suc.2016.11.003

Bobo, 2019, Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: Meta-analysis and trial sequential analysis of prospective observational studies, Surg. Endosc., 33, 1033, 10.1007/s00464-018-06648-z

Ruurda, 2019, Robotic-assisted gastrectomy for gastric cancer: A European perspective, Gastric Cancer, 22, 909, 10.1007/s10120-019-00979-z

Kinami, 2019, Precision surgical approach with lymph-node dissection in early gastric cancer, World J. Gastroenterol., 25, 1640, 10.3748/wjg.v25.i14.1640

Yoshida, 2015, Is conversion therapy possible in stage IV gastric cancer: The proposal of new biological categories of classification, Gastric Cancer, 19, 329, 10.1007/s10120-015-0575-z

Santoro, 2014, Subtotal gastrectomy for gastric cancer, World J. Gastroenterol., 20, 13667, 10.3748/wjg.v20.i38.13667

Dixon, 1971, Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: Ten-year follow-up, Ann. Surg., 173, 26, 10.1097/00000658-197101000-00004

Lise, 1995, Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer, J. Clin. Oncol., 13, 2757, 10.1200/JCO.1995.13.11.2757

Coombes, 1990, A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group, J. Clin. Oncol., 8, 1362, 10.1200/JCO.1990.8.8.1362

Nakajima, 1999, Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: A randomised trial, Lancet, 354, 273, 10.1016/S0140-6736(99)01048-X

Paoletti, 2010, Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer, JAMA, 303, 1729, 10.1001/jama.2010.534

Sakuramoto, 2007, Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine, N. Engl. J. Med., 357, 1810, 10.1056/NEJMoa072252

Van den Ende, T., ter Veer, E., Machiels, M., Mali, R., Nijenhuis, F.A., de Waal, L., Laarman, M., Gisbertz, S.S., Hulshof, M.C.C.M., and van Oijen, M.G.H. (2019). The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers, 11.

Noh, 2014, Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial, Lancet Oncol., 15, 1389, 10.1016/S1470-2045(14)70473-5

Sasako, 2011, Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer, J. Clin. Oncol., 29, 4387, 10.1200/JCO.2011.36.5908

Bang, 2019, KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer, Future Oncol., 15, 943, 10.2217/fon-2018-0581

Yan, 2007, A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer, Ann. Surg. Oncol., 14, 2702, 10.1245/s10434-007-9487-4

Ajani, 2013, National Comprehensive Cancer Network. Gastric cancer, version 2.2013: Featured updates to the NCCN Guidelines, JNCCN, 11, 531

Okines, 2010, On behalf of the ESMO Guidelines Working Group Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 21, v50, 10.1093/annonc/mdq164

Das, 2017, Neoadjuvant chemotherapy: Survival benefit in gastric cancer, Lancet Oncol., 18, e307, 10.1016/S1470-2045(17)30321-2

Hartgrink, 2004, Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial, Eur. J. Surg. Oncol. (EJSO), 30, 643, 10.1016/j.ejso.2004.04.013

Cunningham, 2006, Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer, N. Engl. J. Med., 355, 11, 10.1056/NEJMoa055531

Boige, 2007, Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial, J. Clin. Oncol., 25, 4510, 10.1200/jco.2007.25.18_suppl.4510

Tsai, 2019, No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database, Dig. Surg., 37, 249, 10.1159/000501678

Borg, 2019, Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study, Futur. Oncol., 15, 2723, 10.2217/fon-2019-0243

Shitara, 2012, Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment, Gastric Cancer, 16, 261, 10.1007/s10120-012-0179-9

Kadowaki, 2017, Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy, Cancer Chemother. Pharmacol., 80, 807, 10.1007/s00280-017-3422-6

Hecht, 2016, Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial, J. Clin. Oncol., 34, 443, 10.1200/JCO.2015.62.6598

Tabernero, 2018, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study, Lancet Oncol., 19, 1372, 10.1016/S1470-2045(18)30481-9

Wang, 2017, EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient?derived xenografts with cetuximab, Oncol. Rep., 38, 2387, 10.3892/or.2017.5907

Lordick, 2010, Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Br. J. Cancer, 102, 500, 10.1038/sj.bjc.6605521

Macedo, 2017, Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission?, J. Gastric Cancer, 17, 1, 10.5230/jgc.2017.17.e1

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial, Lancet Oncol., 15, 1224, 10.1016/S1470-2045(14)70420-6

Su, 2014, FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study, Br. J. Cancer, 110, 967, 10.1038/bjc.2013.802

Inokuchi, 2015, Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer, Gastroenterol. Res. Pract., 2015, 1, 10.1155/2015/796380

Ohtsu, 2013, Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study, J. Clin. Oncol., 31, 3935, 10.1200/JCO.2012.48.3552

Ramanathan, 2015, Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005), Cancer, 121, 2193, 10.1002/cncr.29363

Li, 2018, Detection of gastric cancer and its histological type based on iodine concentration in spectral CT, Cancer Imaging, 18, 42, 10.1186/s40644-018-0176-2

Kwee, 2007, Imaging in Local Staging of Gastric Cancer: A Systematic Review, J. Clin. Oncol., 25, 2107, 10.1200/JCO.2006.09.5224

Kwee, 2009, Imaging in assessing lymph node status in gastric cancer, Gastric Cancer, 12, 6, 10.1007/s10120-008-0492-5

Coburn, 2014, Optimal Management of Gastric Cancer: Results from an international RAND/UCLA expert panel, Ann. Surg., 259, 102, 10.1097/SLA.0b013e318288dd2b

Kwee, 2015, Modern imaging techniques for preoperative detection of distant metastases in gastric cancer, World J. Gastroenterol., 21, 10502, 10.3748/wjg.v21.i37.10502

Bruneton, 1996, Primary tumor staging of gastric and colorectal cancer, Eur. Radiol., 6, 140, 10.1007/BF00181129

Huo, 2014, Clinical value of magnetic resonance imaging in preoperative T staging of gastric cancer and postoperative pathological diagnosis, Oncol. Lett., 8, 275, 10.3892/ol.2014.2135

Sohn, 2000, Comparing MR Imaging and CT in the Staging of Gastric Carcinoma, Am. J. Roentgenol., 174, 1551, 10.2214/ajr.174.6.1741551

Kim, 2000, MRI in Staging Advanced Gastric Cancer: Is It Useful Compared with Spiral CT?, J. Comput. Assist. Tomogr., 24, 389, 10.1097/00004728-200005000-00006

Zhong, 2005, Preoperative diagnosis of gastric cancer using 2-D magnetic resonance imaging with 3-D reconstruction techniques, Chin. J. Dig. Dis., 6, 159, 10.1111/j.1443-9573.2005.00224.x

Wang, Z., and Chen, J. (2011). Imaging in assessing hepatic and peritoneal metastases of gastric cancer: A systematic review. BMC Gastroenterol., 11.

Zhang, 2020, The role of MRI in the diagnosis and treatment of gastric cancer, Diagn. Interv. Radiol., 26, 176, 10.5152/dir.2019.19375

Fonocho, 2017, Limitations in the use of 18F-FDG PET in the pre-operative staging of gastric cancer: A case series, Int. J. Surg. Case Rep., 36, 147, 10.1016/j.ijscr.2017.05.026

Stahl, 2003, FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings, Eur. J. Nucl. Med. Mol. Imaging, 30, 288, 10.1007/s00259-002-1029-5

Kinkel, 2002, Detection of Hepatic Metastases from Cancers of the Gastrointestinal Tract by Using Noninvasive Imaging Methods (US, CT, MR Imaging, PET): A Meta-Analysis, Radiology, 224, 748, 10.1148/radiol.2243011362